3rd Annual Brain Metastases Research and Emerging Therapy Conference
17 Jul 2013
We are pleased to welcome you to Marseille for the third Annual Brain Metastases Research and Emerging Therapy Conference. Last year’s successful edition has prompted us to once again organize this conference. Over the past several months, the EORTC has launched the development of a Brain Metastasis platform, created in August 2012, in order to optimally develop and conduct projects focusing on brain metastases.
This research platform brings together the multidisciplinary approach that is needed to develop brain metastases projects across several tumor types and disciplines such as breast cancer, lung cancer, melanoma, imaging, pathobiology and radiation oncology. It is expected that this cross-sectional platform stimulates innovative and insightful research in a collaborative environment in order to improve the standard of care and methodology of clinical research.
Together, the EORTC, GRPCMac and Canceropole PACA have decided to jointly organize the “Annual Brain Metastases Research and Emerging Therapy Conference” which will be held under the auspices of the EORTC. The organizing committee hopes that this meeting will provide an exceptional opportunity for you to share your collective expertise ranging from basic science to new treatments in order to facilitate ongoing studies and lay the foundation for future collaborative projects.
On behalf of the Organizing Committee.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023